Danielle M. Enserro

PhD

Specializing In:

Phase I, II and III clinical trials in gynecologic oncology Endometrial, ovarian and rare tumor trials Cancer prevention and control trials Prognostic and predictive modeling of biomarkers Risk prediction modeling Large observational cohort studies and screening study design

Research Interests:

Endometrial, ovarian and rare tumor trials Cancer prevention and control trial techniques Prognostic and predictive modeling for biomarker studies Translative research studies Risk prediction modeling

About Danielle M. Enserro

Biography:

I am the Associate Director of Biostatistics in the Clinical Trials Development Division (CTDD) of the Department of Biostatistics & Bioinformatics. I am also an appointed Research Assistant Professor in both the Biostatistics & Bioinformatics Department at Roswell Park and the Department of Biostatistics within the School of Public Health & Health Professions at the State University of New York at Buffalo.

In my role as CTDD Associate Director of Biostatistics, I participate in the overall leadership and determination of the scientific direction of the CTDD. I also oversee the CTDD Statistical Programming Team, and I provide and maintain responsibility for statistical collaboration in various CTDD research areas. I design, maintain, and analyze a wide range of clinical studies in collaboration with research clinicians for NRG Oncology and the Gynecologic Oncology Group (GOG) Foundation. I am a certified SAS programmer and I also have experience with R, EAST and PASS.

Prior to beginning my current role, I served as a CTDD Biostatistician for over six years. My time within CTDD has produced more than 11 research publications, including one in NEJM. Most of my expertise is in endometrial, ovarian, and rare tumor cancers. I also work on cancer prevention and control clinical trials through the NRG Oncology NCORP Research Base. I serve as a committee member on several NRG Committees including the Rare Tumor Subcommittee, the NCORP Cancer Prevention and Control Committee, and the NCORP Patient Reported Outcomes Committee.

I received my PhD in Biostatistics from Boston University in 2017. My graduate research work focused on measures of discrimination, reclassification, and calibration for risk prediction modeling.  A portion of my dissertation was published in "Statistics in Medicine" in 2019. I received my MA in Biostatistics from Boston University in 2012 and my BA in Mathematical Science from Elms College in 2006.

During my time at Boston University and for several years afterwards, I worked extensively as a Research Scientist on cardiovascular analyses for the Framingham Heart Study. I contributed to more than 25 research publications in a 10-year span. My focuses included prognostic and predictive biomarker analysis, lifetime heart failure risk over the life course, trajectory modeling and temporal trend analysis, and several studies utilizing the Ideal Cardiovascular Health score.

I also serve as a statistical mentor for the BRIDGES Research Initiative for the Society of Gynecologic Oncology (SGO). I provide statistical mentorship and support to 30 mentees per cycle, and  also present on various statistical topics at meetings.  I have presented on several statistical topic areas including novel trial design and statistics for rare tumor trials, study design considerations for prevention trials, study designs for adaptive trials, and statistical challenges of immunotherapy trials.

 

Positions

Roswell Park Comprehensive Cancer Center
  • Research Assistant Professor of Biostatistics
  • Clinical Trials Development Division Associate Director of Biostatistics
  • Department of Biostatistics & Bioinformatics

State University of New York at Buffalo

  • Research Assistant Professor

Background

Education and Training:

  • 2017 - PhD - Biostatistics, Boston University, Boston MA
  • 2012 - MA - Biostatistics, Boston University, Boston MA

Honors & Awards:

  • 2015 - Boston University School of Public Health's Excellence in Teaching Award

Publications

Full Publications list on PubMed

Pugh SL, Brown PD, Enserro D. Missing repeated measures data in clinical trials. Neuro-Oncology Practice. 2021 Jul;9(1):35-42. PMC8789297.

Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary surgical cytoreduction for recurrent ovarian cancer. New England Journal of Medicine. 2019 Nov 14;381(20):1929-1939. PMC6941470

Enserro DM, Demler OV, Pencina MJ, D’Agostino RB Sr. Measures for evaluation of prognostic improvement under multivariate normality for nested and non-nested models. Statistics in Medicine. 2019 Sept;38(20):3817-3831. PMC6827341

Enserro DM, Vasan RS, Xanthakis V. Twenty-year trends in the American Heart Association Cardiovascular Health Score and impact on subclinical and clinical cardiovascular disease: the Framingham Offspring Study. Journal of the American Heart Association. 2018 June 5; 7(11):e008741. DOI:10.1161/JAHA.118.008741. PMC6015351

Ho JE*, Enserro D*, Brouwers FP*, Kizer JR*, Shah SJ, Psaty BM, Bartz TM, Santhanakrishnan R, Lee DS, Chan C, Liu K, Blaha MJ, Hillege HL, van der Harst P, van Gilst WH, Kop WJ, Gansevoort RT, Vasan RS, Gardin JM, Levy D, Gottdiener JS*, de Boer RA*, Larson MG*. Predicting Heart Failure with Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Subtypes. Circulation: Heart Failure. 2016 June; 9(6):e003116. DOI:10.1161/CIRCHEARTFAILURE.115.003116. *Authors contributed equally. PMC4902276